Journal of Alzheimer's & Dementia Open Access

Apolipoprotein E4 and its Associated Risk to Trigger Alzheimer’s Disease

Faiza Nadeem^* and Sajid Ali Department of Biotechnology, University of Management and Technology, Sialkot, Pakistan
^*Correspondence: Faiza Nadeem, Department of Biotechnology, University of Management and Technology, Sialkot, Pakistan, Email:

Received: 26-May-2023, Manuscript No. IPAD-23-16579; Editor assigned: 29-May-2023, Pre QC No. IPAD-23-16579 (PQ); Reviewed: 12-Jul-2023, QC No. IPAD-23-16579; Revised: 26-Jul-2023, Manuscript No. IPAD-23-16579 (R); Published: 02-Aug-2023, DOI: 10.36648/IPAD.6.4.31

Introduction

Alzheimer’s disorder neurodegeneration is characterized by a specific age related start or progressive failure in function and cognitive as well as specific neurological disorders. Alois Alzheimer identified a patient in 1906 and wrote about their case in 1906, which marked the beginning of the disease known as Alzheimer’s [1].

Alzheimer’s disorder was first linked to the APOE e4 allele, a genetic variant of the Apolipoprotein E (APOE) gene, which control major signaling channels by engaging with sites in the blood plasma and cerebral spinal fluid. Humans have three genotypes of this gene e4, e3 and e2 (APOE), e3 is the most prevalent subsequent to allele e3 and e4. The Apolipoprotein e genes located on the nineteenth chromosome that represent the major biological risk for later onset of dementia [2]. The people with a single copy of the apolipoprotein-4 variant experience a 2 to 3 fold greater probability of Alzheimer’s disorder, whereas people with a pair of copies receive an eight to twelve fold higher chance of developing the disease, in comparison with individuals in the majority of the widespread three quarter variants. Everyone imitate in an apolipoprotein e4 variant has been linked to a greater chance of Alzheimer’s disease as well as an earlier age of cognitive impairment development. Despite the fact that apolipoprotein e4 genotype is a significant biological risk element for dementia [3]. It is also thought that additional aspects such as environment and genetics contribute to onset of dementia.

The human brain has around 86 billion neurons that receive and send data via chemical and electrical impulses that are present in the cerebral cortex. Neurons carry signals form the central nervous system towards organs and muscles throughout the body as well as among various regions in the brain. There are main three components of the majority of neurons are an axon, many dendrites, and a cell body [4]. The body of the cell is the centre of the neuron, contributing to transport biological data, protect the framework of neuron, and generate action. The dendrites are stings of fibers, which emerge from cells throughout the body and receive or analyze information from the axons that are part of other neurons.

The axon, a framework with a long tail, connects the cell body with a unique point known as the axon hillock. Normal age related process causes significant brain shrinkage but does not cause a significant loss of neurons. Conversely, with Alzheimer’s disorder, neurons stops working, loss connection to other neuronal cells, and eventually die. It interferes with essential neural network and neuronal cells, transmission, metabolism, and repair processes [5]. As neurons die across the brain in dementia, many different areas start to contract, which cause alterations in the brains appearance after dementia has taken hold. This widespread process known as neuronal atrophy, results in a large reduction in the size of the brain by the advanced stages of Alzheimer’s disease.

The accumulation of polypeptides named tau protein that contributes to the occurrence as well as growth of dementia. Although tangled exist as an instinctively unstable proteins with no known twisting associated by its behavior, PTMs of the tangles protein are mainly accountable in inappropriate and off attachment to the tiny tubules causing tangles protein accumulation. In contrast, the protein that precedes amyloid has a clarified fundamental makeup, or improper secretase control that results in the development of amyloid peptides as well as subsequent the oligomers and filaments. These tangles are inappropriate tau buildups that develop within axons [6]. Six extremely soluble peptide variants known as tangled protein that are created by alternate splicing from microtubules associated protein. The substantial tangles deposits may be found inside the cell, in which instance may induce apoptotic process. Additionally, clumps may be expelled from the cell, and they lead to aggravation on their own, primarily due to their impact on the microglial cells. According to neural tangles, the main trigger of dementia, tangles excessive phosphorylation prevents tangles from attaching to tiny tubules and making more tangled that are more likely to the aggregation. β amyloid accumulation increases produce dementia by setting off harmful process that result in chronic degeneration [7]. The amyloidogenic route, which generates plaques composed of amyloid, is the route of action, which triggers dementia to proceed.

Although difficulties and adverse impacts, numerous investigations have established the medical treatments are effective in treating Alzheimer. Now, memantine, a drug that blocks the activity of the NMDA receptor or inhibitors of cholinesterase are authorized medications for dementia. The most common widely used medications for preventing or treatment of dementia comprise the drug memantine and donepezil, which work through processes like reduced plaque formation and the receptor for NMDA stimulation. Some of the effects of pharmaceuticals offered for the treatment of dementia include decreased glutamate and increased acetylcholine pharmaceuticals can help slow down the growth of dementia or remembering degradation [8]. Controlling the potential recurrence of dementia or the adverse effects of memantine, rivastigmine, aducanmab and donepezil in human tests, in the laboratory, or animal model experiments requires a novel pharmacologic method or approach and researchers looked at the effects of these medications in preventing the progression of dementia or explore potential brain influencing processes [9].

Literature Review

Babataunde oluwafemi adetuyi, peace Abiodun Olajide, et al., demonstrated that, the existence of APOE is one of the primary genetic risk factors for AD (Alzheimer’s Disease) (apolipoprotein E4 allele) [10]. APOE is a polymorphic protein of lipid that is important for the transportation of cholesterol in the brain. Additionally, it plays a critical role in the breakdown of glucose, neuroinflammation, and neuronal signaling. The three different Apolipoprotein alleles are E2, E3, and E4. The E3 allele is the one that is found most frequently in humans. The E4 allele is associated with a higher risk of Alzheimer’s disease, but the E2 allele is linked with a slightly lower risk [11]. It has taken a lot of work to understand the molecular mechanisms behind APOE related genetic risk, which has led to the development of cellular and animal models. Results from these concepts indicate that APOE4 may worsen amyloid plaque load in a dose-dependent manner and may promote tau disease progression in a manner related to isoform dependent [12].

Samira Parhizakr, et al., demonstrated that, the most common type of neurological condition, dementia exhibits neurological inflammation as a key process in degeneration [13]. The major biological associated risk of the development of dementia, a protein called apolipoprotein e4, interacts with the protein amyloid plaques, which are neurofibrillary the protein tau tangles, and neural inflammation in order to impact the start and development of the illness. The two main types immune cells in the brain, astrocytes and microglia, are immunological-vigilant and provide both immunologic defenses and maintenance tasks to maintain neurological health [14]. It grows more and more clear that throughout state of disorders, these cells of the immune system gradually loss their ability to control metabolic processes or immune regulation processes, which encourages prolonged infection that induced degeneration. In particular, apolipoprotein e4 specifically affect amyloid deposits, tau tangles and interferes with glial, or astrocytes immune regulating process, that results in long term inflammation and dementia [15].

Deepthi Rapaka, et al., demonstrated that the combination of pathogenic A and tau enzymes causes the chronic degenerative disease vascular dementia that is distinguished as chronic inflammatory disease. Some various factors to be considered in neurodegeneration include accelerated neuronal damage and increased immune response. Neuromodulators are manufactured and released by the metabolic mechanism that present within microglia. The use of cannabinoid system’s health potential in the treatment of dementia is a relatively recent development. Inflammatory responses are controlled by the stimulation both endocannabinoid functions and the endocannabinoid pathway. The analysis examines the connection among both neuropathology in Alzheimer’s and the microglia cannabinoid network [16]. Evidence in favours of the pharmaceutical drugs ability to regulate the endocannabinoid programs antiinflammatory effects also are discussed (Table 1).

Table 1: Literature review on Alzhemier disease.

Isaac Asante, et al., demonstrated that, in vascular dementia, a continuous phase of untreated disease is exctricably linked to the modification of cerebral triglycerides. The report reviews how expressing the protein of lipids E4 variant impacts kinds of cerebral cell a by encouraging a prolonged immune reaction [17]. We concentrate on apolipoprotein E4 stimulation on calcium ions phospholipase A2 but also its impact on eicosanoids, eicosapentaenoic acid, and arachidonic acid pathway involving inside the cerebral between such point’s views that impact on cerebral triglycerides. Because of the neuronal death, distinct varieties of cerebral neurons, including fibroblasts, macrophages, and neurons, as well as the peripheral nerve region, exhibit distinctive pathological characteristics may affect its activities and have distinctive seen throughout profiles. Researchers suggest using works regarding morphological characteristics for examine the processes behind Alzheimer using unicellular kinds derived in cerebral of individuals with various elders, sexualities, clinical risk phases, and nutritional as well as biological origins. Therefore, evolution for dietary and pharmaceutical therapies for Alzheimer’s disease is likely to be guided by a greater understanding of a visual cortex biological immune process [18].

Shaowei wang, et al., demonstrated that, research processes behind the relationship between proteins of lipid E4 (APOE4) and a higher reaction in neuropathology as well as the possibility of acquiring early Alzheimer’s disorder remain unclear. In AD brain amyloid, the pathogenic activation enzyme calcium dependent cytosolic phospholipase A2 is activated more than usual. It is unsure that how APOE4 genotypes and cPLA2 activities are linked.

Allan Butterfield, et al., demonstrated that, the prevalence of vascular dementia in the older people is extremely high. Therefore, dementia and degeneration are not typical outcomes of ageing. The research report describes mitochondrial biochemical alterations within Alzheimer’s disorder neurodegeneration. Several systems were also noted for possible dementia effective treatments. Oxidant instability from inside brain, which disturbs physiological functions, is among the primary causes of dementia. Many biological reactions, particularly some linked to organelles, like the electron transfer chain, produce reactive O₂ molecules [19]. At under regulation or maintained as appropriate stages, certain reactive O₂ species frequently participate in intercellular communication. When there is oxidant instability, reactive oxygen O₂ species develop uncontrollable can lead to a variety of abnormalities in metabolic processes in the body, and that in turn causes damage to cells, several modified mechanisms involve, and other, disrupted mammals regulator of autophagy system, defective lipogenesis, calcium modulation, and metabolism. It might be deal to identify treatment strategies in slowing the onset of dementia as in elderly by comprehending why reactive O₂ species may cause such modifications (Supplementary Table 1).

Yanhui Zhang, et al., demonstrated that, vascular dementia, one of the widespread form of memory loss in older people, long-term, developing neurological ailment that there are now on treatments. According to the research, both growth and to accelerate Alzheimer’s disease are highly linked with such an instability in the radioactive elements inside the hippocampus, particularly copper, mercury, and aluminum. As comprehend steel processes or healing process of dementia, a lot of work has been done. Recent research reveals how one of the mechanisms underlying dementia will involve associations between cerebral radioactive elements or apoe E, the highest heritability component in delayed dementia. Therefore, researches highlight the important aspects about how transition metals or apolipoprotein affect dementia development.

Laura Trujillo-Estrada, et al., demonstrated that, approximately forty-five “mm” individuals are suffered by the cognitive illness known as Alzheimer’s disorder. Genetically modified mice strains are assisted significantly to our understanding of the inflammatory conditions underlying the symptoms and signs of dementia. Nevertheless, research integration for potential preclinical medicines to the clinic has been hindered by the limited capacity of such in experimental systems that faithfully reproduce the physiology of the viral diseases. Researches emphasize a number of significant predictions and experimental for dementia in this review that have been identified in genetically mice strains. Additionally, they discuss about the limitations of recent experimental animals and the importance of create credible simulations for such scattered version of such illness, that makes up the bulk of patients with Alzheimer’s disease, along with cellular functions simulations to enhance the efficiency of converting findings onto medications for people.

Yu Yamazki Na Zhao, et al., demonstrated that, Apolipoprotein E (APOE) isoform seems to be significant biological hazard factor for delayed dementia, with the apolipoprotein e4 variant expanded danger as well as the apolipoprotein e2 allele decreasing risk compared to the typical apolipoproteine3 variant. Substantial research from the both clinical and fundamental studies reveals the apolipoprotein e4 drives quicker as well as more extensive plaque disease mostly in neurons with apolipoprotein e4 bearers, which is one key pathway through which APOE4 increases the risk of AD. There are more and more systems, which have been reported to still be variably that altered by apolipoprotein alleles, both A-dependent and A-independent. In instance, increasing data suggests the cognitive pathogenesis, amyloid plaques neurotoxic, or microglia reactions towards Alzheimer diseases are all impacted by apolipoprotein. A number of cerebral cellular functions, such as lipid transport, synapse stability and neuroplasticity, glycogen synthesis, and cerebrovascular function, are also affected by apolipoprotein e4, both in a pathologic form or with diminished effectiveness. Therefore, we examine one of latest events in scientific and clinical studies on the function of apolipoprotein in the pathogenesis of Alzheimer’s disease. We also go through how precision medicine can be used to address apolipoprotein for alzheimer disease treatment.

Tosha Williams, et al., demonstrated, apolipoprotein E 4 variant is major genetic risk factors for vascular dementia AD. A significant transporter of cholesterol in the nervous system is a heterogeneous lipoprotein called apolipoprotein e4. Additionally, it has a role in a number of biological processes include metabolism, neuronal signaling and neurotoxicity. The three apolipoprotein allele frequency variations E4, E2, and E3 are the most frequent in mammals, and E3 being the least frequent. The hazard of dementia is enhanced, when the E4 genotype is present, but the risk is decreased by the allele E2. The development of animal and cellular modeling has received a lot of attention in the quest to comprehend the biological mechanisms behind the hereditary risk associated with apolipoprotein. The system analysis shows the apolipoprotein e4 increases the amount of amyloidosis deposition in some kind of a daily dosage way, or might, in such an isoform-dependent way, potentially accelerate tau pathology. Another research has revealed that regulation of tau or a pathogenesis. Moreover, it is not fully understood how plasma apolipoprotein can indirectly change brain activity by altering peripheral biochemical functions. The existing data combined indicate that APOE may affect numerous transcription factors, so researches have searched for treatments that will impair apolipoprotein pathogenic factors, while maintaining or improving its appropriate supports. In addition to discussing, additional approaches which show potential for the future, this will focus in some of the targeted therapies that are now being researched to attack apolipoprotein e4 in the attempt to prevent or curing dementia.

Neural stem cells are the main producers of APOE, a crucial lipids transporter protein inside the nervous system. The largest type of cells in the cortex, hepatocytes act as the primary network supporting neuron. In the synthesis and distribution of cholesterol to the brain, they are essential, for spontaneous and delayed forms of vascular dementia, the three basic apolipoprotein variants in living beings, APOE3, and APOE4 show a large biological impact on the prevalence and onset age. People who carry the four genotype are more likely to develop dementia than people who carry the two allele, who are immune. The significance of isoform to the beginning of dementia has been focus of conflicting research, and much remains unknown regarding this proteins function in illness. Therefore, we examine the competing theories that are being presented in the literature as well as the methods that have been thought to be appropriate for treating apolipoprotein as a potential dementia therapeutic strategy. Furthermore, we offer our viewpoint on the justification for addressing apolipoprotein as well as the difficulties associated with the painkiller of this domain.

Discussion

Although there is currently no known cure for dementia, it is more crucial to lower exposure, offer preventative measures, and precisely evaluate abnormalities. According to the research review, numerous attempts are made to identify dementia using different algorithms based on microsimulation strategies nevertheless, it is still difficult to uncover specific features that are capable of recognizing dementia quite earlier. In order to increase the accuracy of recognition techniques, future research will concentrate on the gathering and analyzing of new traits that are more likely to help in identifying indicators of dementia as well as on the removal of duplicate or unnecessary characteristics from previous set of characteristics.

Makis Tzioras, et al., discussed that, amyloid or tauphosphorylated forms are two pathogenic accumulations of protein that are present in the cerebral cortex along with gradual memory loss in elderly people who have dementia. Due to junction destruction or loss of neuronal cells, the illness causes a weakening of the cerebral. In either individuals as well as animal specimens of Alzheimer's disease, loss of synaptic connections is highly correlated with decline in cognitive function. In fact, research points to the possibility that solubility sorts of tangled and the protein amyloid may diffuse throughout the neural network and produce synaptotoxicity. One theory is that cells known as glial cells in the nervous system abnormally consume connections to regulate the trans-synaptic transmission of disease in conjunction with these neurological modifications. Effective medicines for both the treatment and the avoidance of dementia are now absent, but it will be crucial to comprehend how synapse destruction takes place if novel approaches are to be developed.

Allan Butterfield, et al., discussed that, the prevalence of vascular dementia in the older people is extremely high. Therefore, dementia and degeneration are not typical outcomes of ageing. The research report describes mitochondrial biochemical alterations within Alzheimer’s disorder neurodegeneration. Several systems were also noted for possible dementia effective treatments. Oxidant instability from inside brain, which disturbs physiological functions, is among the primary causes of dementia. Many biological reactions, particularly some linked to organelles, like the electron transfer chain, produce reactive O₂ molecules. At under regulation or maintained as appropriate stages, certain reactive O₂ species frequently participate in intercellular communication. When there is oxidant instability, reactive oxygen O₂ species develop uncontrollable can lead to a variety of abnormalities in metabolic processes in the body, and that in turn causes damage to cells, several modified mechanisms involve, and other, disrupted mammals regulator of autophagy system, defective lipogenesis, calcium modulation, and metabolism. It might be deal to identify treatment strategies in slowing the onset of dementia as in elderly by comprehending why reactive O₂ species may cause such modifications.

Yijing Tang, et al., discussed that, the most prevalent neurological condition that is dependent on age is memory loss. Despite extensive research on dementia through numerous perspectives, neurodegeneration cognitive is still no viable treatment for dementia. This is partly because dementia is not fully understood mechanistically. We primarily concentrate on the conversation as well as analysis of the reasons for dementia from a mechanical standpoint. Despite the fact that several alzheimer processes highlight various genetic or cell level processes involved in Alzheimer pathology, but may not eliminate one another. Rather, a number of them might collaborate to start, commence, encourage and promote the disorder's commencement or development. Some dementia processes, such as the process of amyloid accumulation system, the bacterial neuroinflammation process, and the pathogenic cross-seeding process, may also apply to other amyloid illnesses, such as diabetes of type II and Parkinson's illness. These shared pathways between Alzheimer as well as other aggregate illnesses reveal additionally how each aggregate illness develops, but additionally way these illnesses transfer their abnormalities to one another. These shared mechanisms will help develop new approaches to alzheimer prevention and therapy.

Yanhui Zhang, et al., discussed that, vascular dementia, one of the widespread forms of memory loss in older people, long term, developing neurological ailment that there are now on treatments. According to the research, both growth and to accelerate Alzheimer’s disease are highly linked with such instability in the radioactive elements inside the hippocampus, particularly copper, mercury, and aluminum. As comprehend steel processes or healing process of dementia, a lot of work has been done. Recent research reveals how one of the mechanisms underlying dementia will involve associations between cerebral radioactive elements or apoe E, the highest heritability component in delayed dementia. Therefore, researches highlight the important aspects about how transition metals or apolipoprotein affect dementia development.

Yuxuan Dai, et al., discussed that, memory loss along with dementia are hallmarks of the degenerative neurotoxic condition known as dementia. However, plaques of amyloid or tangles of neurons are the most noticeable pathological signs of dementia. The creation of alzheimer disorder modifying medications has occurred with practically all medications terminated it is difficult. Due to the following reasons, the hypothesis of the amyloid burst theory has been a number of amyloid targeting strategies' shortcomings. Considering that, clinical trials of Amyloid-(A) effective therapy showed certain encouraging findings that confirm this concept. There are still prospects. In this overview, we will address the most recent developments in treatment strategies related to amyloidogenic processes or assess the benefits and drawbacks of each approach. As well emphasis the present situation of the most popular chemotherapy as well as address its next phase of advancement.

Conclusion

Laura Trujillo-Estrada, et al. discussed that, approximately forty-five “mm” individuals are suffered by the cognitive illness known as Alzheimer’s disorder. Genetically modified mice strains are assisted significantly to our understanding of the inflammatory conditions underlying the symptoms and signs of dementia. Nevertheless, research integration for potential preclinical medicines to the clinic has been hindered by the limited capacity of such in experimental systems that faithfully reproduce the physiology of the viral diseases. Researches emphasize a number of significant predictions and experimental for dementia in this review that has been identified in genetically mice strains. Additionally, they discuss about the limitations of recent experimental animals and the importance of create credible simulations for such scattered version of such illness, that makes up the bulk of patients with Alzheimer’s disease, along with cellular functions simulations to enhance the efficiency of converting findings onto medications for people.

References

1. Asante I, Louie S, Yassine HN (2022) Uncovering mechanisms of brain inflammation in Alzheimer’s disease with APOE4: Application of single cell-type lipidomics. Ann N Y Acad Sci. 1518(1):84-105.

   [Crossref] [Google Scholar] [PubMed]

2. Dai Y, Lei C, Zhang Z, Qi Y, Lao K, Gou X (2022) Amyloid-beta targeted therapeutic approaches for Alzheimer’s disease: Long road ahead. Curr Drug Targets. 23(11):1040-1056.

   [Crossref] [Google Scholar] [PubMed]

3. Lennol MP, Sanchez-Dominguez I, Cuchillo-Ibanez I, Camporesi E, Brinkmalm G, et al. (2022) Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients. Alzheimers Res Ther. 14(1):1-19.

   [Crossref] [Google Scholar] [PubMed]

4. Mashal Y, Abdelhady H, Iyer AK (2022) Comparison of tau and amyloid-β targeted immunotherapy nanoparticles for Alzheimer’s disease. Biomolecules. 12(7):1001.

   [Crossref] [Google Scholar] [PubMed]

5. Eljamay SM, Elshalwi HE (2022) Electric vehicle integration with energy sources : Problem and solution. Appli Sci. 1(1):17-20.

   [Google Scholar]

6. Parhizkar S, Holtzman DM (2022) APOE mediated neuroinflammation and neurodegeneration in Alzheimer’s disease. Semin Immunol. 59:101594.

   [Crossref] [Google Scholar] [PubMed]

7. Qadir MI, Qammar K (2022) Alzheimer’s disease and role of apolipoprotein E in Alzheimer’s disease. Middle East Appl Sci Technol. 5(1):38-43.

   [Google Scholar]

8. Rapaka D, Bitra VR, Challa SR, Adiukwu PC (2021) Potentiation of microglial endocannabinoid signaling alleviates neuroinflammation in Alzheimer’s disease. Neuropeptides. 90:102196.

   [Crossref] [Google Scholar] [PubMed]

9. Rummel NG, Butterfield DA (2022) Altered metabolism in alzheimer disease brain: Role of oxidative stress. Antioxid Redox Signal. 36(16-18):1289-1305.

   [Crossref] [Google Scholar] [PubMed]

10. Saeedi M, Mehranfar F (2022) Challenges and approaches of drugs such as memantine, donepezil, rivastigmine, and aducanumab in the treatment, control and management of Alzheimer’s disease. Recent Pat Biotechnol. 16(2):102-121.

    [Crossref] [Google Scholar] [PubMed]

11. Lopez JA, Gonzalez HM, Leger GC (2019) Alzheimer’s disease. Handb Clin Neurol. 167:231-255.

    [Crossref] [Google Scholar] [PubMed]

12. Suidan GL, Ramaswamy G (2019) Targeting apolipoprotein E for Alzheimer’s disease: An industry perspective. Int J Mol Sci. 20(9):2161.

    [Crossref] [Google Scholar] [PubMed]

13. Tang Y, Zhang D, Gong X, Zheng J (2022) A mechanistic survey of Alzheimer’s disease. Biophys Chem. 281:106735.

    [Crossref] [Google Scholar] [PubMed]

14. Trujillo-Estrada L, Sanchez-Mejias E, Sanchez-Varo R, Garcia-Leon JA, Nunez-Diaz C, et al. (2022) Animal and cellular models of Alzheimer’s disease: Progress, promise, and future approaches. Neuroscientist. 28(6):572-593.

    [Crossref] [Google Scholar] [PubMed]

15. Tzioras M, McGeachan RI, Durrant CS, Spires-Jones TL (2023) Synaptic degeneration in alzheimer disease. Nat Rev Neurol. 19(1):19-38.

    [Crossref] [Google Scholar] [PubMed]

16. Wang S, Li B, Solomon V, Fonteh A, Rapoport SI, et al. (2022) Calcium dependent cytosolic phospholipase A2 activation is implicated in neuroinflammation and oxidative stress associated with APOE4. Mol Neurodegener. 17(1):1-21.

    [Crossref] [Google Scholar] [PubMed]

17. Williams T, Borchelt DR, Chakrabarty P (2020) Therapeutic approaches targeting apolipoprotein e function in Alzheimer’s disease. Mol Neurodegener. 15(1):1-19.

    [Crossref] [Google Scholar] [PubMed]

18. Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G (2019) Apolipoprotein E and alzheimer disease: Pathobiology and targeting strategies. Nat Rev Neurol. 15(9):501-518.

    [Crossref] [Google Scholar] [PubMed]

19. Zhang Y, Gao H, Zheng W, Xu H (2022) Current understanding of the interactions between metal ions and apolipoprotein E in Alzheimer’s disease. Neurobiol Dis. 172:105824.

    [Crossref] [Google Scholar] [PubMed]